Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes

Sarandeep Singh Malhi, Abhishek Budhiraja, Sumit Arora, Kiran R. Chaudhari, Kunal Nepali, Raj Kumar, Harmik Sohi, Rayasa S.R. Murthy

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.

Original languageEnglish
Pages (from-to)63-74
Number of pages12
JournalInternational Journal of Pharmaceutics
Volume432
Issue number1-2
DOIs
Publication statusPublished - Aug 1 2012
Externally publishedYes

Fingerprint

Folic Acid
Liposomes
Doxorubicin
Oxidation-Reduction
Mitochondria
Neoplasms
KB Cells
Ligands
Confocal Microscopy
Cations
Oxidative Stress
Pharmaceutical Preparations

Keywords

  • Anticancer therapy
  • Mitocancerotropic liposomes
  • Mitochondrial delivery
  • Redox cycler
  • ROS

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. / Malhi, Sarandeep Singh; Budhiraja, Abhishek; Arora, Sumit; Chaudhari, Kiran R.; Nepali, Kunal; Kumar, Raj; Sohi, Harmik; Murthy, Rayasa S.R.

In: International Journal of Pharmaceutics, Vol. 432, No. 1-2, 01.08.2012, p. 63-74.

Research output: Contribution to journalArticle

Malhi, Sarandeep Singh ; Budhiraja, Abhishek ; Arora, Sumit ; Chaudhari, Kiran R. ; Nepali, Kunal ; Kumar, Raj ; Sohi, Harmik ; Murthy, Rayasa S.R. / Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. In: International Journal of Pharmaceutics. 2012 ; Vol. 432, No. 1-2. pp. 63-74.
@article{8a56d0e67799482aa1616f4b658731fb,
title = "Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes",
abstract = "Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.",
keywords = "Anticancer therapy, Mitocancerotropic liposomes, Mitochondrial delivery, Redox cycler, ROS",
author = "Malhi, {Sarandeep Singh} and Abhishek Budhiraja and Sumit Arora and Chaudhari, {Kiran R.} and Kunal Nepali and Raj Kumar and Harmik Sohi and Murthy, {Rayasa S.R.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.ijpharm.2012.04.030",
language = "English",
volume = "432",
pages = "63--74",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes

AU - Malhi, Sarandeep Singh

AU - Budhiraja, Abhishek

AU - Arora, Sumit

AU - Chaudhari, Kiran R.

AU - Nepali, Kunal

AU - Kumar, Raj

AU - Sohi, Harmik

AU - Murthy, Rayasa S.R.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.

AB - Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.

KW - Anticancer therapy

KW - Mitocancerotropic liposomes

KW - Mitochondrial delivery

KW - Redox cycler

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=84861604566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861604566&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2012.04.030

DO - 10.1016/j.ijpharm.2012.04.030

M3 - Article

VL - 432

SP - 63

EP - 74

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -